Dossier
Penn Medicine
Coverage of Penn Medicine in the Nexus archive.
- Can GLP-1s Treat Cancer? What the Latest Science Says About Ozempic’s Newest Benefit
GLP-1 receptor agonists, including Ozempic, show potential in reducing cancer risk through weight loss, inflammation reduction, and metabolic improvements. Early studies link their use to a 30-35% lower breast cancer incidence in women and reduced risks for colorectal, endometrial, ovarian, liver, and brain cancers.
- Breaking down findings of new study on weight loss drugs and breast cancer
Researchers from Penn Medicine found that women taking GLP-1 drugs are less likely to be diagnosed with breast cancer, according to a new study. Dr. Celine Gounder analyzed the findings to determine if the drugs caused the difference.